Leukemia, lymphoma, and myeloma account for approximately 10 percent of all cancer diagnoses in the United States, according to the Leukemia and Lymphoma Society. Thus, hematologic malignancies are actively being investigated by biotech and pharma companies. However, hematologic models are challenging to evaluate in a disease-relevant context.
Utilization of bioluminescence imaging (BLI) endpoints with luciferase-enabled cell lines allows us to tightly triage and stage study cohorts, assess systemic tumor burden in vivo with whole body imaging, and longitudinally assess drug treatment responses in a quantitative dataset with improved relevance to the clinical disease setting.
We offer more than 50 different hematologic tumor lines, of both human and murine origin. We bring over a decade of industry-leading experience and expertise in model selection, study design, study execution, image acquisition and proprietary data analysis of disseminated tumor models. The power of this experience results in the delivery of high-quality, decision-enabling datasets.